



Statement from Novo Nordisk Ireland Limited on the supply of Novo Nordisk products to Ireland post Brexit

Dublin, Ireland, 22 August 2019 - In light of continued uncertainty around Brexit and the future relationship of the UK with the European Union, Novo Nordisk Ireland would like to inform patients using our medicinal products that we have taken steps to ensure continuity of supply regardless of the outcome.

All of our medicinal products come from continental Europe and currently these arrive in Ireland via the UK land-bridge. By-passing the UK has been tested as part of Novo Nordisk's Brexit risk planning. In the event of a no-deal withdrawal of the UK from the EU on 31 October 2019 or if we see a breakdown in transit time, products will be delivered directly to Ireland from continental Europe, thereby by-passing the UK.

Novo Nordisk has also increased stock levels in Ireland to ensure continuity of supply to Irish patients after 31 October 2019 and will closely monitor stock levels going forward.

We therefore advise patients taking Novo Nordisk medicines to continue to access their prescribed medicines as they normally do.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#)

For queries or further information please contact us:

Clinical, Medical and Regulatory 1850 665 665
department

infoireland@novonordisk.com

IE19NNG00006; Date of preparation: August 2019

The Apis bull logo is a registered trademark owned by Novo Nordisk A/S

Directors: Matt Regan (Irish), Jesper Wenzel Larsen (Swiss), Tomas Haagen (Danish). General Manager: Owen Treacy (Irish)

Novo Nordisk Ltd.	First Floor, Block A The Crescent Building Northwood Business Park Santry, Dublin 9 D09 X8W3 Ireland	Telephone: +353 1 8629700 Telefax: +353 1 8629 725	E-mail: infoireland@novonordisk.com Internet: www.novonordisk.ie	Reg. No.: 61378 VAT No.: 4510223A
--------------------------	---	---	--	--
